Inmune Bio's market cap is currently ―. The company's EPS TTM is $-1.67; its P/E ratio is -5.27; Inmune Bio is scheduled to report earnings on May 1, 2024, and the estimated EPS forecast is $-0.53. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 28.00K	$ 43.00K	$ 46.00K	$ 38.00K	$ 97.00K
Gross Profit	$ 28.00K	$ 43.00K	$ 46.00K	$ 38.00K	$ 97.00K
EBIT	$ -575.50M	$ 559.47M	$ -5.78M	$ 5.77M	$ -8.27M
EBITDA	$ -575.45M	$ 559.53M	$ -5.72M	$ 5.84M	-
Net Income Common Stockholders	$ -8.53M	$ -8.53M	$ -6.50M	$ 6.39M	$ -5.83M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 35.85M	$ 41.81M	$ 47.83M	$ 51.00M	$ 52.15M
Total Assets	$ 57.00M	$ 62.70M	$ 69.72M	$ 73.98M	$ 81.80M
Total Debt	$ 10.44M	$ 12.91M	$ 15.39M	$ 15.37M	$ 15.31M
Net Debt	$ -25.41M	$ -28.90M	$ -32.44M	$ -35.63M	$ -36.84M
Total Liabilities	$ 18.86M	$ 17.97M	$ 19.07M	$ 18.68M	$ 81.80M
Stockholders Equity	$ 37.34M	$ 43.93M	$ 50.65M	$ 55.30M	$ 60.10M
Cash Flow	-
Free Cash Flow	$ -3.40M	$ -4.26M	$ -3.16M	$ -1.15M	$ -5.70M
Operating Cash Flow	$ -3.40M	$ -4.26M	$ -3.16M	$ -1.15M	$ -5.70M
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	$ -2.50M	$ -1.73M	-	-	-

Currency in USD

Inmune Bio Earnings and Revenue History

Income Statement >

Inmune Bio Debt to Assets

Balance Sheet >

Inmune Bio Cash Flow

Cash Flow >

Inmune Bio Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing